Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer

Inclusion Criteria: * Singed informed consent. * Women with Age ≥ 18 years. 1. -In women of childbearing age it should be documented: a) negative pregnancy test in serum at the beginning of the study (14 days before the start of QT-RT); b) Accept the use of some method of contraception approved by your attending physician during the study and 12 weeks after the treatment has ended. 2. -In postmenopausal women (surgical or natural menopause) at least one of the following parameters must be met for inclusion. * Previous bilateral oophorectomy * Age ≥ 60 years * Age \<60 years and amenorrhea for at least 12 months and levels of follicle stimulating hormone and estradiol within postmenopausal interval parameters. * Diagnosis of CaCu EC IB2 mg/dl With histological confirmation (epidermoid, adenocarcinoma or adenoescamoso). * Patients who are candidates for treatment with concomitant QT / RT. * ECOG 0-2. * Measurable disease by CT scan and magnetic resonance imaging of the pelvis according to the RECIST criteria v1.1 * No previous treatment. * Creatinine clearance ≥ 60 ml / min calculated by the CKD-EPI formula. * Patients with adequate hematological and hepatic functioning, defined by the following parameters: 1. Hb equal to or greater than 10g /l. (Transfusion prior to treatment is allowed to reach this level of hemoglobin). 2. Leukocytes greater than or equal to 4000 / mm3. 3. Platelets equal to or greater than 100,000mm3. 4. Total bilirubin ≤1.5 times the upper limit of normal (ULN) and. Transaminases less than 1.5 times the LSN * Patients with a prior diagnosis of the following comorbidities: * Diabetes mellitus type 2, which has: fasting serum glucose \<250 mg/dl. * Systemic arterial hypertension G1 or G2 according to CTCAE v4.03 * Child Pugh A liver disease * Cardiovascular diseases such as: Ischemic heart disease undergoing asymptomatic treatment, without clinical data of stable or unstable angina or for acute myocardial infarction. * Compensated heart failure in functional class I of the New York Heart Association. * Systemic Lupus Erythematosus with mild or inactive lupus activity (less than or equal to 4 points according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Exclusion Criteria: * Patients with a second neoplasm. * Pregnant or lactating patients. * Patients with small cell and / or neuroendocrine CaCu. * Patients with impaired renal function with a GFR \<or equal to 60ml / min calculated by the CKD-EPI formula * Patients with a history of active TB (TB) * Patients with a history of Human Immunodeficiency Virus (HIV) infection * Patients with vesico-vaginal or vesicorectal fistulas at diagnosis * Concomitant treatment with another experimental drug. Social, family or geographical conditions that suggest a poor attachment to the study Criteria Interruption of Treatment (Withdrawal of patients) A patient will be discontinued from the study under the following circumstances: * Evidence of disease progression. * If treating physician considers that a change of therapy may benefit the patient. * If patient withdrew consent * Due to unmanageable toxicity By pregnancy or if the patient does not wish to continue using the contraceptive methods indicated by the attending physician